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A b s t r a c t
Background: Mortality and morbidity in patients with cardiac resynchronisation therapy (CRT) remain very high. Prognostic 
evaluation of CRT candidates might be useful for the assessment of CRT indications, directing further therapy, counselling, etc.
Aim: Our goal was to assess the prognostic value of various parameters in order to construct a risk score that could predict 
long-term mortality and morbidity during the initial evaluation of CRT candidates.
Methods: This was a retrospective, single-centre, large cohort study involving consecutive heart failure patients who underwent 
CRT device implantation. In order to build a prediction model, 28 parameters were analysed using uni- and multivariate Cox 
models and Kaplan-Meier survival curves.
Results: Data from 552 patients were used for the long-term outcome assessment. During nine years of follow-up, 232 pa-
tients met the primary endpoint of death and 128 patients were hospitalised for heart failure. The strongest and clinically 
most relevant predictors were selected as the final model. AL-FINE is the acronym for these six predictors: Age (> 75 years), 
non-Left bundle branch block morphology (according to Strauss criteria), Furosemide dose (> 80 mg), Ischaemic aetiology, 
New York Heart Association class (> III), and left ventricular Ejection fraction (< 20%). Depending on the number of AL-FINE 
score points, overall mortality at seven years was in the range of 28% (0–1 points) to 74% (3–6 points).
Conclusions: A novel, multiparametric CRT risk score was constructed on the basis of simple and recognised clinical, electro-
cardiographic, and echocardiographic parameters that show a significant add-on effect on mortality in this specific population. 
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INTRODUCTION
Cardiac resynchronisation therapy (CRT) improves the sur-
vival in patients with moderate and advanced heart failure 
(HF). Despite this fact, mortality and morbidity in CRT 
patients remain very high; different CRT trials and studies 
have indicated the 5–7-year mortality to be around 20% to 
70%, with a median survival after device implantation of 
approximately five years [1–7]. Although many factors that 
predict the outcome have been identified in patients with 
HF, few variables enable to predict it consistently. Moreover, 
in HF patients with CRT, certain prognostic factors might 
play a greater role, while the impact of others might be 
minimised by this interventional therapy. The add-on effects 
of independent prognostic factors warrant the construction 
of a multiparametric risk score to improve the prediction 
of outcomes.
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Risk stratification scores applicable for other patient popula-
tions, like euroSCORE for coronary heart disease patients, SCORE 
risk chart for the general cardiovascular risk stratification [8], 
or CHA2DS2-VASc score for atrial fibrillation patients, have 
been accepted as very useful. Similar prognostic evaluation 
of CRT patients would have obvious potential applications for 
the assessment of CRT indications, guiding further therapy, 
counselling, and other purposes. 
Our goal was to assess the prognostic value of various 
clinical parameters in order to construct a simple risk score 
that could help in predicting long-term mortality and mor-
bidity at the time of initial evaluation of candidates for CRT 
device implantation.
METHODS
Patient population
This was a retrospective, single-centre, large cohort study 
including consecutive HF patients who underwent CRT device 
implantation in our institution (a university/teaching hospital), 
from February 2006 to December 2014. CRT devices were 
implanted according to recognised indications and using 
standard transvenous techniques, as described previously [9]. 
Variables analysed
In order to build a predictive model, several relevant pa-
rameters useful in predicting mortality in CRT patients were 
gathered. These included:
 — basic clinical data: age, sex, and body mass index;
 — major comorbidities: diabetes mellitus, permanent atrial 
fibrillation, and hypertension;
 — HF aetiology: categorised as ischaemic or non-ischaemic. 
Ischaemic aetiology was defined as a history of myo-
cardial infarction or any significant stenotic lesions in 
coronary angiography;
 — New York Heart Association (NYHA) functional class; 
the highest class assigned in medical records was used;
 — electrocardiographic (ECG) data including: (i) baseline 
QRS morphology, categorised as left bundle branch block 
(LBBB), according to the Strauss definition (requirement 
for a mid-QRS notch in at least two left ventricular (LV) 
leads and longer QRS duration), or non-LBBB; and 
(ii) preimplantation QRS duration, assessed according to 
the global QRS method, i.e. from the earliest onset of 
the QRS of 12 simultaneously recorded standard ECG 
leads to the last observable QRS component in any of 
these leads, as recommended by the American Heart 
Association and the World Health Organization [10]. 
For ECG assessment, the digital recording system (EP 
Lab System PRO, Boston Scientific, Boston, MA, USA) 
and digital callipers were used with high paper speed 
(100 ms/s) and appropriately adjusted with respect to 
amplitude augmentation;
 — echocardiographic data: pre-implantation LV ejection 
fraction (EF), LV end-diastolic diameter (LVEDD), and 
the severity of mitral regurgitation;
 — biochemical data: sodium plasma concentration, haemo-
globin concentration, presence of hypercholesterolaemia, 
and alanine aminotransferase level;
 — glomerular filtration rate (GFR) measured according 
to the Modification of Diet in Renal Disease for-
mula: GFR (mL/min/1.73 m2) = 175 × (serum creati-
nine)–1.154 × (age)–0.203 × (0.742 if female);
 — use of cardiovascular drugs: diuretics, b-blockers, angio-
tensin converting enzyme inhibitors, angiotensin receptor 
blockers, aldosterone antagonists, and acetylsalicylic acid;
 — dose of furosemide; in patients taking torasemide, the 
dose was calculated using the conversion of 1 mg tor-
semide to 2 mg of furosemide;
 — procedure-related data: upgrade or de novo implantation 
of a CRT-pacing or CRT-defibrillation device.
Measures of clinical outcome
The primary endpoint was all-cause mortality, and the sec-
ondary endpoint was all-cause mortality and HF-related hos-
pitalisations. Data concerning mortality and hospitalisations 
were collected through medical records from our outpatient 
department (where most CRT patients were followed regularly 
at six- to ten-month intervals) as well as through the analysis 
of all available medical documentation and phone interviews 
with patients and their relatives. In the absence of any contact 
with a patient or their family, the survival status was deter-
mined from the national Polish PESEL registry. Urgent heart 
transplantation was classified as death. 
Statistical analysis
Continuous variables are presented as means and standard 
deviations, and categorical variables as numbers and per-
centages. Survival time distribution was visualised using the 
Kaplan-Meier curves. The risk score was constructed from 
multivariate Cox proportional hazards (CPH) model (more 
methodological details are given in the results section). There 
were no significant violations of the proportionality assump-
tion that underlies the CPH method. The discriminative power 
of the Cox model was measured using Harrell’s C‐statistic. 
All statistical analyses were performed using R 3.4 software, 
with p‐values < 0.05 considered significant.
RESULTS
During the study, 590 patients underwent CRT device im-
plantation procedures. Of these, 38 were excluded due to 
the following reasons: unsuccessful LV lead implantation 
(15 patients; success rate of 97.5%), incomplete medical 
records (eight patients), late LV lead repositioning/loss of 
CRT (five patients), upgrade to triple site pacing (two LV 
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leads; seven patients), and implementation of a non-standard 
resynchronisation type (direct His bundle pacing, dual-site 
right ventricular pacing; three patients). Thus, data from 
552 patients were used for the long-term outcome assess-
ment. Baseline characteristics of these patients are presented 
in Table 1.
During the nine years of observation (average follow-up 
time of 46 ± 28 months), 232 patients met the primary 
endpoint of death from any cause or urgent heart transplan-
tation. There were 101 deaths due to HF worsening, and 
23 sudden deaths, with four patients undergoing urgent heart 
transplantations. Eighteen deaths were classified as non-HF 
cardiac in nature and 44 as non-cardiac. The cause of death 
could not be determined in the remaining 42 patients. The 
survival rates at the end of years 1–7 were 89.7%, 80.7%, 
70.6%, 63.6%, 57.2%, 52.7%, and 46.9%, respectively. Dur-
ing the same time period, 128 patients required unplanned 
hospitalisation for HF-related reasons, 132 were hospitalised 
for other cardiac-related reasons, and 107 were hospitalised 
for non-cardiac reasons. Of the 128 patients suddenly hos-
pitalised for HF-related reasons, 68 patients eventually died. 
Thus, 292 patients met the composite endpoint of all-cause 
death or hospitalisation for HF.
Outcome predictors and the AL-FINE CRT  
risk score construction
Several of the analysed variables had prognostic value. Re-
sults of the univariate and multivariate Cox analyses for the 
all-cause mortality and all-cause mortality or HF hospitalisa-
tion are presented in Tables 2 and 3. The predictive model 
including all variables had a C-statistic of 0.716 for all-cause 
mortality and 0.693 for the secondary endpoint. Initially, in 
order to build a new risk score, we calculated Cox models 
with all possible subsets of two to six predictors. The result-
ing models with predictive abilities similar to the full model 
were then assessed using clinical knowledge. The model 
with both high C index (0.713 for and 0.682 for the primary 
and secondary endpoints, respectively) and clinically most 
meaningful/practical predictors was selected as the final 
one. AL-FINE is the acronym for the six predictors included 
in the final model: Age, non-LBBB morphology, Furosemide 
dose, Ischaemic aetiology, NYHA class, and left ventricular EF. 
These were the variables responsible for 99.6% of the 
prognostic power of the model (for all-cause mortality) that 
included all variables. To further simplify the risk assessment, 
continuous predictors incorporated in the model were 
transformed into categorical variables using arbitrary cut-off 
points. Kaplan-Meier survival curves for all-cause mortality 
for all six variables are presented in Figure 1. Each of these 
unfavourable characteristics was then assigned one AL-FINE 
CRT risk score point. This resulted in a major simplifica-
tion at a minimal cost to the predictive power as shown by 
C-statistics of 0.701 and 0.661 for the primary and secondary 
endpoints, respectively (Table 4). All-cause mortality increased 
with the accumulation of the risk factors. Hazard ratio for 
2 or 3–6 AL-FINE score points (calculated vs. 0–1 points) was 
2.45 (95% confidence interval [CI] 1.66–3.61, p < 0.001), and 
4.72 (95% CI 3.28–6.80, p < 0.001), respectively. Depending 
on the number of AL-FINE score points, overall mortality at 
Table 1. Basic patient characteristics
Basic clinical data and comorbidities:
Age [years] 67.8 ± 10.4
Male sex 451 (81.7)
BMI [kg/m2] 28.3 ± 3.9
Permanent atrial fibrillation 156 (28.3)
Diabetes mellitus 243 (44.0)
Hypertension 406 (73.6)
Heart failure-related data:
Ischaemic aetiology 349 (63.2)
NYHA functional class:
Class II 47 (8.5)
Class III 434 (78.6)
Class IV 71 (12.9)
Electrocardiographic and echocardiographic data:
LBBB (Strauss) 226 (40.9)
QRS duration [ms] 172.7 ± 33.1
LVEF [%] 24.3 ± 6.8
LVEDD [mm] 69.4 ± 9.4
Mitral regurgitation grade > 3 52 (9.4)
Biochemical data:  
Sodium [mmol/L] 138.6 ± 3.54
ALAT [U/L] 29.0 ± 18.9
Hypercholesterolaemia 355 (64.3)
Haemoglobin [g/dL] 13.7 ± 1.6
Pharmacological therapy:
ACEI/ARB 479 (86.6)
b-blocker 524 (94.9)
Aldosterone 362 (65.6)
ASA 426 (77.2)
Loop diuretic 511 (92.6)
Furosemide dose [mg] 73.2 ± 63.4
Procedure-related data:
Device upgrade 145 (26.3)
CRT-P device 247 (44.7)
Data are presented as number (percentage) or mean ± standard devia-
tion. ACEI/ARB — angiotensin converting enzyme inhibitor/angiotensin 
receptor blocker; ALAT — alanine aminotransferase; ASA — acetylsali-
cylic acid; BMI — body mass index; CRT-P — cardiac resynchronisation 
therapy-pacing; LBBB — left bundle branch block; LVEF — left ventri-
cular ejection fraction; LVEDD — left ventricular end-diastolic diameter; 
NYHA — New York Heart Association
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Table 2. Predictors of all-cause mortality and all-cause mortality or heart failure-related hospitalisation in univariate Cox analysis
Predictor All-cause mortality All-cause mortality/HF hospitalisation
HR (95% CI) p HR (05% CI) p
LBBB (Strauss) 0.84 (0.65–1.09) 0.197 0.53 (0.41–0.68) < 0.001
Age (per 10 years) 1.31 (1.14–1.49) < 0.001 1.17 (1.04–1.31) 0.010
Male sex 1.13 (0.79–1.63) 0.494 1.04 (0.76–1.42) 0.823
Ischaemic aetiology 1.51 (1.14–1.99) 0.004 1.34 (1.05–1.70) 0.019
NYHA class > 3 2.48 (1.88–3.28) < 0.001 2.06 (1.60–2.64) < 0.001
Persistent AF 0.90 (0.67–1.21) 0.472 1.09 (0.84–1.40) 0.519
LVEF (per 10%) 0.72 (0.59–0.88) 0.001 0.79 (0.67–0.95) 0.010
LVEDD (per 10 mm) 1.08 (0.94–1.24) 0.290 1.07 (0.94–1.21) 0.315
Severe mitral insufficiency 1.17 (1.02–1.35) 0.030 1.25 (1.10–1.42) 0.001
Diabetes mellitus 1.30 (1.00–1.68) 0.048 1.36 (1.08–1.71) 0.008
eGFR (per 10 mL/min/1.73 m2) 0.92 (0.87–0.98) 0.011 0.91 (0.86–0.96) 0.001
Hypercholesterolaemia 0.80 (0.62–1.05) 0.111 0.85 (0.67–1.08) 0.172
BMI (per 5 kg/m2) 0.78 (0.67–0.91) 0.001 0.93 (0.82–1.06) 0.269
Hypertension 0.92 (0.69–1.22) 0.562 1.20 (0.92–1.56) 0.169
Preimplantation QRS (per 50 ms) 0.98 (0.80–1.19) 0.828 0.88 (0.73–1.05) 0.149
Furosemide daily dose (per 50 mg) 1.42 (1.31–1.54) < 0.001 1.41 (1.31–1.52) < 0.001
Haemoglobin (per 1 g/dL) 0.94 (0.87–1.02) 0.148 0.94 (0.87–1.01) 0.074
Sodium (per 5 mmol/L) 0.72 (0.60–0.86) < 0.001 0.77 (0.66–0.90) 0.001
ALAT (per 10 IU/L) 1.05 (0.98–1.12) 0.173 1.07 (1.01–1.14) 0.028
ASA 1.22 (0.87–1.69) 0.249 0.97 (0.73–1.28) 0.827
ARB 0.76 (0.45–1.29) 0.308 0.70 (0.44–1.13) 0.147
ACEI 0.93 (0.68–1.27) 0.633 0.94 (0.71–1.25) 0.685
b-blocker 0.45 (0.27–0.74) 0.002 0.61 (0.38–0.98) 0.040
Diuretic 3.75 (1.77–7.98) 0.001 5.14 (2.42–10.89) < 0.001
Aldosterone antagonist 1.02 (0.77–1.35) 0.872 0.98 (0.76–1.25) 0.863
Device upgrade 1.35 (1.02–1.79) 0.036 1.33 (1.03–1.71) 0.027
CRT-P 0.84 (0.65–1.09) 0.192 0.89 (0.70–1.12) 0.308
AF — atrial fibrillation; CI — confidence interval; EF — ejection fraction; eGFR — estimated glomerular filtration rate; HF — heart failure;  
HR — hazard ratio; other abbreviations — see Table 1
Table 3. Significant predictors of all-cause mortality and all-cause mortality or heart failure-related hospitalisation in multivariate 
Cox analysis
Predictor* All-cause mortality All-cause mortality or HF hospitalisation
HR (95% CI) p HR (95% CI) p
LBBB (Strauss) 0.67 (0.48–0.94) 0.019 0.66 (0.49–0.89) 0.007
Age (per 10 years) 1.41 (1.19–1.67) < 0.001 1.10 (0.95–1.28) 0.203
NYHA class > 3 1.90 (1.41–2.58) < 0.001 1.56 (1.19–2.05) 0.001
Persistent AF 0.63 (0.45–0.87) 0.006 0.75 (0.57–1.00) 0.046
LVEF (per 10%) 0.75 (0.60–0.95) 0.016 0.82 (0.67–1.00) 0.054
Preimplantation QRS (per 50 ms) 0.78 (0.60–1.00) 0.047 0.76 (0.61–0.94) 0.012
Furosemide daily dose (per 50 mg) 1.25 (1.12–1.39) < 0.001 1.21 (1.10–1.33) < 0.001
Sodium (per 5 mmol/L) 0.82 (0.69–0.98) 0.032 0.86 (0.73–1.01) 0.070
b-blocker 0.50 (0.29–0.87) 0.013 0.79 (0.47–1.33) 0.377
Loop diuretic 2.13 (0.97–4.70) 0.060 3.10 (1.43–6.75) 0.004
*Multivariate Cox model included all predictors listed in Table 2; abbreviations — see Tables 1 and 2
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seven years was within the range of 28% to 74%. Similarly, 
for the secondary endpoint, the risk also increased with the 
number of AL-FINE CRT risk score points: HR of 2.21 (95% 
CI 1.60–3.06, p < 0.001) and 3.41 (95% CI 2.51–4.64, 
p < 0.001), for 2 or 3–6 AL-FINE score points, respectively. 
Figures 2 and 3 demonstrate Kaplan-Meier survival curves 
for 0–1, 2, and 3–6 AL-FINE score points for all-cause mor-
tality and all-cause mortality or HF-related hospitalisation, 
respectively. Additionally, a Kaplan-Meier survival curve for 
the preimplantation QRS duration > 150 ms was calculated 
(Suppl. Fig. 1 — see journal website) because this is a widely 
recognised prognostic parameter in CRT patients. 
Figure 1. Kaplan-Meier survival curves for all-cause mortality. The six variables selected for the AL-FINE CRT score: Age, non-LBBB 
morphology, Furosemide dose, Ischaemic aetiology, NYHA class, and left ventricular EF. A. Age; B. Left bundle branch block 
(LBBB; Strauss); C. Furosemide dose; D. Aetiology; E. New York Heart Association class; F. Left ventricular ejection fraction;  
DCM — dilated cardiomyopathy
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DISCUSSION
The major finding of the current study was that the constructed 
prognostic AL-FINE CRT score was based on simple, readily 
available clinical variables and was capable of predicting prog-
nosis in CRT patients at the preimplantation stage. This allows 
stratification of patients into those with good (seven-year sur-
vival rate: 72%), intermediate, and poor prognosis (seven-year 
survival rate: 26%). 
Predictors of mortality used  
in the AL-FINE CRT score
Age 
Age is a recognised prognostic factor in HF. In the ESC-HF 
Long-Term Registry, mortality rates in patients > 75 years old 
were over two times higher than in patients < 65 years old 
[11]. In the MADIT-CRT cohort, which included patients with 
mild HF, patients > 74 years old did not benefit from CRT in 
terms of lower mortality in a long-term observation [12]. In the 
current study, age > 75 years significantly and independently 
predicted a worse survival. In patients with more advanced 
HF or more comorbidities, the impact of age might be even 
more pronounced. The combination of older age and any two 
other high-risk characteristics in our study placed patients in 
the group with the lowest survival rate.
LBBB
Left bundle branch block is considered a major prognostic fac-
tor in HF patients [13, 14]. However, while LBBB is a marker 
of a worse prognosis in patients not treated with CRT, in 
CRT patients, the presence of LBBB is associated with better 
prognosis. This reflects the specificity of resynchronisation 
therapy, which is based on correcting asynchronous contrac-
tion caused by LBBB, and, in its essence, it is aimed at “cur-
ing” LBBB. For this to occur, LBBB needs to be present. Of 
note, LBBB was a better prognostic factor than preimplanta-
tion QRS duration > 150 ms (Suppl. Fig. 1 — see journal 
website). However, not all studies confirm the importance 
of LBBB morphology. We believe that this is related to the 
differences in LBBB definitions, precision in ECG assessment, 
and differences in acute outcome of the procedure (presence 
Figure 2. Kaplan-Meier survival curves for all-cause mortality 
based on the number of AL-FINE CRT score points
Figure 3. Kaplan-Meier survival curves for all-cause mortality or 
heart failure (HF)-related hospitalisation based on the number 
of AL-FINE CRT score points
Table 4. AL-FINE CRT risk score predictors in multivariate Cox analysis
Predictor All-cause mortality All-cause mortality or HF hospitalisation
HR (95% CI) p HR (95% CI) p
Age > 75 years 1.68 (1.25–2.25) 0.001 1.30 (0.99–1.71) 0.056
Non-LBBB (Strauss) 1.62 (1.22–2.16) 0.001 1.76 (1.37–2.27) < 0.001
Furosemide dose > 80 mg/day 2.01 (1.50–2.69) < 0.001 2.03 (1.56–2.65) < 0.001
Ischaemic aetiology 1.40 (1.04–1.88) 0.025 1.19 (0.92–1.54) 0.184
NYHA class 4 1.95 (1.40–2.73) < 0.001 1.58 (1.15–2.16) 0.004
EF < 20% 1.60 (1.19–2.14) 0.002 1.37 (1.04–1.79) 0.023
Abbreviations — see Tables 1 and 2
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of acute QRS narrowing, i.e. correction of LBBB). It was 
recently shown by us and others that long-term survival in 
CRT patients depends greatly on the applied LBBB definition 
[13, 15]. Various LBBB definitions result in diagnosing LBBB 
in significantly different groups of patients, and this leads to 
different prognostic values. It is unfortunate that some studies 
aimed at the construction of a CRT score did not even specify 
the definition used for diagnostic or prognostic purposes in 
their study [2, 5]. It seems that the recently proposed Strauss 
criteria are the best method for identification of patients with 
a true LBBB, i.e. those with baseline potential to favourably 
respond to biventricular pacing. In the current study, the lack 
of LBBB morphology according to the Strauss criteria plus 
any other two disadvantageous characteristics at the preim-
plantation stage identified patients with a high mortality risk, 
perhaps because CRT cannot influence the natural course of 
HF in such patients.
Heart failure aetiology
Several studies found that ischaemic aetiology of HF is related 
to a lesser benefit from CRT in terms of reverse remodelling 
when compared to patients with idiopathic cardiomyopathy 
[16, 17]. Conversely, non-ischaemic aetiology was among 
the strongest factors associated with reverse remodelling 
following CRT in the MADIT-CRT cohort [18]. When known 
relationships between reverse remodelling and mortality are 
taken into consideration, it is not surprising that ischaemic 
aetiology is associated with worse survival. Such a relation-
ship was present in the current study and was reported 
previously by others. Notably, a meta-analysis based on five 
randomised CRT trials reported HR of 1.64 for all-cause 
mortality for ischaemic aetiology [19]. The negative impact 
of ischaemic aetiology on CRT outcomes might reflect the 
fact that the presence of post-myocardial infarction scarring 
results in some degree of non-reversible asynchrony or lower 
contribution of asynchrony to the systolic dysfunction of the 
left ventricle. Myocardial scarring is also probably linked with 
ineffective biventricular pacing (e.g. latency and the resulting 
wide LV-paced QRS complexes with ensuing small contribu-
tions of LV activation to the biventricular QRS complex and 
LV contraction) [20, 21].
NYHA functional class IV
Despite the fact that the NYHA functional class is a rather 
crude and subjective assessment of symptoms, it was shown 
to predict mortality in chronic HF in several studies [22, 23]. 
The impact of the NYHA functional class on mortality in 
CRT patients was less thoroughly investigated; however, it 
can be easily appreciated when mortality in CRT trials that 
included NYHA class III–IV patients (COMPANION, MIRACLE, 
CARE-HF) and trials that predominantly included patients in 
NYHA class I–II (MADIT-CRT, RAFT) is compared. Moreover, 
in three of the previous CRT scores, NYHA class was the 
strongest predictor of mortality in multivariate analysis [2, 5, 
24]. Similarly, in the current study the highest assigned NYHA 
class was on par with the furosemide dose as the strongest 
predictor of long-term mortality and morbidity.
LVEF 
Studies involving general HF patients showed contradictory 
results with regard to the prognostic value of echocardio-
graphic LVEF. This might reflect the inaccuracy of measuring 
EF by echocardiography [25]. However, in CRT cohorts, the 
prognostic importance of LVEF was confirmed by several stud-
ies [2, 5, 7, 24, 26], and our results are concordant with these 
in this respect. Hypothetically, EF might be prognostically more 
important in CRT patients due to the fact that in patients with 
a low EF, the magnitude of correctable dyssynchrony might 
be smaller, resulting in a markedly worse response to CRT. 
Dose of loop diuretic
Loop diuretics are commonly used in symptomatic patients 
with HF to prevent fluid retention and to control symp-
toms. The current guidelines assigned class I recommenda-
tions for such treatment in patients with signs or symptoms 
of hypervolaemia. A meta-analysis has shown that in patients 
with chronic HF, diuretics reduce the risk of death [27]. 
However, several studies have shown that higher diuretic 
doses are associated with worse survival [28–30], suggesting 
that the furosemide dose might be a potent prognostic fac-
tor that is rarely considered or reported. We believe that the 
prognostic value of a loop diuretic dose comes from it being 
a marker of HF severity and from the higher prevalence of 
concomitant illnesses, as some studies have suggested [31]. 
However, a reverse association was also discussed: diuretics 
could worsen the HF course by activating neuroendocrine 
systems, renin-angiotensin-aldosterone, and renal dysfunction 
that together facilitate disease progression [32]. A cut-off dose 
of 80 mg furosemide per day to define a high and low loop 
diuretic dose, used for prognostic purposes in the current 
study, was already proposed and was associated with a worse 
outcome in previous studies [32–34]. Our study is the first to 
show the prognostic importance of the furosemide dose in 
CRT patients. Of note, in every potential CRT candidate, this 
variable is easy to obtain at no extra cost. 
Other multiparametric CRT scores 
Most previous CRT studies have focused on isolated risk fac-
tors such as HF aetiology or QRS morphology, and only a few 
recent studies proposed multiparametric risk scores dedicated 
to the assessment of CRT patients (EAARN, VALID-CRT, 
CRT-SCORE, and L2ANDS2). Only two of these scores (EAARN 
and CRT-SCORE) are applicable, like the AL-FINE CRT score, 
for preimplantation assessment of long-term (i.e. > five years) 
overall mortality risk. Also, some general prognostic scores can 
be used for CRT patients, e.g. the Seattle Heart Failure Model. 
However, with the exception of the EAARN score, they are 
rather complicated and therefore less practical for everyday 
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application because they include up to 23 parameters (and/or 
some require dedicated applications or calculators for score 
determination). Despite simplification, the predictive power 
of our score (Harrel C-statistic of 0.701) does not seem to be 
inferior to the other scores. The VALID-CRT score reported 
a C-statistic of 0.70, the CRT-SCORE had an area under the 
curve (AUC) of 0.748, and the AUC of the Seattle Heart 
Failure Model equalled 0.64 [2, 35]. Apart from simplicity, 
another distinct feature of our score is the attention to pre-
implantation QRS morphology. It is the unique study that 
applied the new, more precise definition of LBBB (Strauss 
criteria), which is known to impact long-term prognosis by 
identifying patients with the greatest potential for response 
to biventricular pacing. 
Clinical application 
In order to enhance the implementation in clinical practice, 
the proposed risk score was simplified to include as few as 
six readily available and straightforward variables. These vari-
ables have been shown to be related with a poor outcome in 
other studies and were also included in other more complex 
CRT scores [2, 5, 35], which strongly suggests their universal 
applicability to other CRT populations. We believe that the 
AL-FINE CRT risk score may positively impact the management 
of CRT patients at all stages of care. At the preimplantation 
stage, patient selection is of the utmost importance. Regard-
ing the cost-effectiveness and complication burden, CRT 
should preferentially be proposed to potential responders. An 
AL-FINE score of 0 points was related to a seven-year survival 
rate of 72%, while in patients with high-risk characteristics (two 
or more points) the survival rate at seven years was only 26%. 
Estimation of life expectancy after a CRT procedure is part of 
the initial assessment at the preimplantation stage. A high-risk 
score should alert both the physician and the patient to as-
sess the long-term benefit of the procedure more realistically. 
High-risk scores could also be useful later, at the implantation 
stage, to identify “special care” patients, in whom the implan-
tation procedure could require more experienced implanters 
in order to maximise the benefit. Achievement of technically 
correct LV capture might not be an adequate endpoint of the 
procedure in such patients. Perhaps extra measures should 
be implemented on an obligatory basis in order to improve 
the outcome. This could include more meticulous LV lead 
positioning guided by local delay mapping, LV-paced QRS 
morphology assessment, and acute QRS shortening. 
At the postimplantation stage, a high AL-FINE CRT score 
might identify patients that require more frequent follow-up 
visits and also, perhaps, early revision of the pacing strategy 
in case of a lack of response, i.e. echocardiographic optimisa-
tion of pacing parameters, upgrade to His bundle pacing, or 
deactivation of the BiV pacing in patients with persistent QRS 
prolongation (presumed desynchronisation effect).
The retrospective nature of the study and inclusion of 
patients at a single centre may have introduced bias. However, 
our cohort was representative of patients who underwent CRT 
implantation in different studies, and the mortality rate was 
within the expected range.
In conclusion, a novel, multiparametric CRT risk score 
was constructed on the basis of simple and recognised clinical, 
electrocardiographic, and echocardiographic parameters that 
show a significant add-on effect on mortality in this specific 
population. Clinical application of the AL-FINE risk score might 
be beneficial and warrants validation in other CRT cohorts. 
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